2 weeks Ago By ABMN Staff
Raymond James Financial Inc. acquired a new position in Genmab A/S ( NASDAQ:GMAB – Free Report ) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 118,002 shares of the company’s stock, valued at approximately $2,463,000.
Several other hedge funds also recently bought and sold shares of GMAB. Two Sigma Advisers LP lifted its holdings in Genmab A/S by 84.1% in the 3rd quarter.
Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after purchasing an additional 280,900 shares in the last quarter. FMR LLC raised its holdings in shares of Genmab A/S by 13.5% during the 3rd quarter.
FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after acquiring an additional 33,076 shares in the last quarter. ABC Arbitrage SA bought a new position in shares of Genmab A/S during the 4th quarter valued at approximately $3,692,000. AIMZ Investment Advisors LLC bought a new position in Genmab A/S during the fourth quarter valued at $3,525,000.
Finally, Y Intercept Hong Kong Ltd increased its holdings in shares of Genmab A/S by 371.0% in the 4th quarter. Y Intercept Hong Kong Ltd now owns 73,696 shares of the company’s stock worth $1,538,000 after buying an additional 58,048 shares during the last quarter.
Institutional investors own 7.07% of the company’s stock. Genmab A/S Stock Down 1.
2 % Shares of Genmab A/S stock opened at $19.90 on Friday. The company has a market cap of $13.
17 billion, a P/E ratio of 11.44, a PEG ratio of 2.65 and a beta of 0.
98. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $30.
50. The firm’s 50 day moving average price is $20.89 and its 200-day moving average price is $21.
88. Analyst Upgrades and Downgrades GMAB has been the subject of a number of analyst reports. William Blair upgraded Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th.
BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Truist Financial lowered their target price on shares of Genmab A/S from $50.00 to $45.
00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th.
Finally, Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock.
Based on data from MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus price target of $41.33. Get Our Latest Report on GMAB About Genmab A/S ( Free Report ) Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. See Also Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S ( NASDAQ:GMAB – Free Report ).
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter ..
